Teva exec says pharma needs to pay attention to its reputation; academics who serve on boards of healthcare companies face potential conflicts of interest; WHO recommendation will boost number of people taking anti-retrovirals

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration